More News
18 October 2022
Eureka Therapeutics Announces License with the National Cancer Institute to Advance GPC2 ARTEMIS® T Cell Therapy for Neuroblastoma18 October 2022
Merck and the Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Tuberculosis Antibiotic Candidates17 October 2022
Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies12 October 2022
Tavros Therapeutics and Vividion Therapeutics Announce Strategic Collaboration to Discover and Enhance Targeted Oncology Programs12 October 2022
Ascidian Therapeutics Launches to Rewrite RNA12 October 2022
Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Small Molecule Activators of AMPK12 October 2022
Illumina Launches Strategic Research Collaboration with AstraZeneca to Accelerate Drug Target Discovery6 October 2022
Nested Therapeutics Launches With $125 Million Financing6 October 2022
Amphista Therapeutics partners with Domainex to advance portfolio of drug discovery projects targeting protein degradation5 October 2022
Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System5 October 2022
Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target3 October 2022
Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine3 October 2022
Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement30 September 2022
Ventus Therapeutics Enters Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program29 September 2022
Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc28 September 2022
Sudo Biosciences Raises $37M Series A Financing to Advance Precision TYK2 Therapeutics28 September 2022
Arsenal Biosciences Announces Joint Discovery Collaboration with Genentech to Identify Features of Successful T-Cell Therapies for Oncology28 September 2022
Scribe Therapeutics Announces Research Collaboration with Sanofi to Accelerate Breakthrough CRISPR-based Cell Therapies for Cancer22 September 2022
GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr21 September 2022
Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor21 September 2022
Sesen Bio and Carisma Therapeutics Announce Merger Agreement21 September 2022
Octagon Therapeutics Enters Inflammation-Focused Research Alliance with Novo NordiskNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports